Mepact (Mifamurtide)

Mifamurtide activates the intracellular NOD2 receptor on macrophages, initiating a signaling cascade that releases cytokines and chemokines. This activation enhances the innate immune response, enabling macrophages to recognize and destroy residual tumor cells after surgery.

The specific dose and infusion schedule of Mepact are determined by the prescribing oncologist based on the patient’s age, weight, and treatment protocol. The product is supplied as a 1 mg lyophilized powder for reconstitution and intravenous administration.

The safety of Mepact in pregnancy and lactation has not been established. It is classified as pregnancy category unknown, and use is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant.

To order Mepact, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Mepact differs from conventional chemotherapy by targeting the immune system rather than directly killing tumor cells. While standard agents such as methotrexate, doxorubicin, and cisplatin act cytotoxically, Mepact stimulates macrophage activity via NOD2, offering a complementary mechanism that can improve survival when combined with standard regimens.

Mepact should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The lyophilized powder remains stable in its original vial until reconstitution for intravenous infusion.

Mepact is supplied as a lyophilized powder that is reconstituted with a suitable diluent and administered by intravenous infusion over a prescribed period, typically under clinical supervision with monitoring of vital signs.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, cytokine release syndrome, significant hypotension, hepatic enzyme elevation, and rare thromboembolic events. Patients should be closely monitored during and after infusion for any signs of these reactions.

Mepact is contraindicated in patients with known hypersensitivity to Mifamurtide or any component of the formulation, and it should be avoided in individuals with active uncontrolled infections or severe immunodeficiency where immune activation could be harmful.